Molecular diagnostics are well-established in clinical medicine. Nonetheless, the markets for these tests remain one of the most attractive growth opportunities in the in vitro diagnostics industry.

Next-generation sequencing (NGS) platforms, along with immunotherapies like checkpoint inhibitors, have brought the promise of precision medicine for cancer patients closer to reality. Terence Rhodes, ...

ROCKVILLE, Md. – May 27, 2025 – The Association for Molecular Pathology, the premier global molecular diagnostic professional society, today announced the release of a three-part series of scientific ...

REDMOND, Wash.--(BUSINESS WIRE)--Anavasi Diagnostics, an NIH/RADx funded medical technology company developing novel molecular diagnostic testing for the point-of-care (POC) market, announced the Food ...

The Southern blot, which detects specific DNA sequences, was one of the first molecular diagnostic methods to be widely adopted. 2 This type of probe-based assay uses a single-stranded oligonucleotide ...

Milestone clears path for rapid market entry of Nanopath's first-in-class point-of-care platform addressing a leading health condition CAMBRIDGE, Mass., Nov. 18, 2025 /PRNewswire/ -- Nanopath, a point ...

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key ...

GraftAssure technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian siteGraftAssureDx FDA IVD approval application 95% complete at yea ...